IOXILAN

Details

Stereochemistry	MIXED
Molecular Formula	C18H24I3N3O8
Molecular Weight	791.1119
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCCO)=C1I

InChI

InChIKey=UUMLTINZBQPNGF-UHFFFAOYSA-N

InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32)

HIDE SMILES / InChI

Molecular Formula	C18H24I3N3O8
Molecular Weight	791.1119
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.ncbi.nlm.nih.gov/books/NBK26369/

Ioxilan is a nonionic X-ray contrast agent approved by the United States Food and Drug Administration for X-ray imaging contrast enhancement. Ioxilan can be administered intravenously for excretory urography and contrast-enhanced computed tomography (CT) imaging of the head and body. Ioxilan can also be given intraarterially for cerebral arteriograpy, coronary arteriography and left ventriculography, visceral angiography, aortography, and peripheral arteriography.

CNS Activity

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Contrast agent 13 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020316Orig1s028lbl.pdf	Diagnostic		Approved 8583	OXILAN-300 Approved Use INTRAARTERIAL: OXILAN® Injection (300 mgI/mL) is indicated for cerebral arteriography. OXILAN® Injection (350 mgI/mL) is indicated for coronary arteriography and left ventriculography, visceral angiography, aortography, and peripheral arteriography. INTRAVENOUS: OXILAN® Injection (300 mgI/mL) and OXILAN® Injection (350 mgI/mL) are indicated for excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body. Launch Date 1995

T_1/2

Value	Dose	Co-administered	Analyte	Population
23.5 min DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020316s029lbl.pdf	72.8 g single, intravascular dose: 72.8 g route of administration: Intravascular experiment type: SINGLE co-administered:		IOXILAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
13.1 min DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020316s029lbl.pdf	72.8 g single, intravascular dose: 72.8 g route of administration: Intravascular experiment type: SINGLE co-administered:		IOXILAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020316s029lbl.pdf	72.8 g single, intravascular dose: 72.8 g route of administration: Intravascular experiment type: SINGLE co-administered:		IOXILAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020316s029lbl.pdf	72.8 g single, intravascular dose: 72.8 g route of administration: Intravascular experiment type: SINGLE co-administered:		IOXILAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY34266	https://www.001chemical.com/chem/107793-72-6
Alfa Chemistry	AP107793726	https://reagents.alfa-chemistry.com/product/ioxilan-cas-107793-72-6-1366.html
Ambinter	Amb22055548	http://www.ambinter.com/reference/22055548
Avantor Inc	101095-240	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101095-240
Avantor Inc	101097-070	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101097-070
BioSynth	J-002011	https://www.biosynth.com/en/products/all-products/products/J-002011.html
BLD Pharm	BD134822	http://www.bldpharm.com/products/107793-72-6.html
Boerchem	BC678009	http://www.boerchem.com/?product_39658.html
Chem Scene	CS-0031230	http://www.chemscene.com/107793-72-6.html
ChemMol	44010108	http://www.chemmol.com/chemmol/44010108.html
Chemspace	CSSS00020617586	https://chem-space.com/CSSS00020617586
Finetech	FT-0627286	http://www.finetechnology-ind.com/prod/detail/pub/107793-72-6.html
Glentham Life Sciences	GP6623	http://www.glentham.com/products/product/GP6623/
MedChem Express	HY-109513	https://www.medchemexpress.com/ioxilan.html
Molcore	MC34266	https://www.molcore.com/product/107793-72-6
MolPort	MolPort-027-948-870	https://www.molport.com/shop/molecule-link/MolPort-027-948-870
Smolecule	S576412	https://www.smolecule.com/products/s576412
THE BioTek	bt-370899	https://www.thebiotek.com/product/others/bt-370899
Yuhao Chemical	RT1900	http://www.chemyuhao.com/107793-72-6.html

PubMed

Title	Date	PubMed
Dimethyl 5-amino-2,4,6-triiodo-isophthalate.	2010-01-16	21579785
Contrast-induced nephropathy morbidity and mortality following percutaneous coronary intervention.	2009-12-15	19962490
Contrast induced nephropathy in urology.	2009-12-04	19955665
Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention.	2009-06-15	19539072
Ethyl 3-carb-oxy-5-nitro-benzoate.	2009-04-30	21583976
Methyl 3-carboxy-5-nitrobenzoate.	2009-01-17	21581938
Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial.	2008-09-03	18768415
Risk of thrombogenicity among nonionic radiocontrast agents.	2008-07	18599893
A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity.	2007-11-14	18001477
Transient interruption of contrast on CT pulmonary angiography: proof of mechanism.	2007-05	17527114
Adrenocortical carcinoma: contrast washout characteristics on CT.	2006-07	16794135
Quantitation of regional cerebral blood flow: the next chapter in digital subtraction angiography.	2006-04	16629744
Comparison of asymmetry in cerebral blood flow between brain hemispheres using digital subtraction angiography.	2006-04	16629736
Decrease in fluoroscopic cardiac silhouette excursion precedes hemodynamic compromise in intraprocedural tamponade.	2005-11	16253913
Polyp size at CT colonography after electronic subtraction cleansing in an anthropomorphic colon phantom.	2005-07	15987967
Effect of nonionic radiocontrast agents on the occurrence of contrast-induced nephropathy in patients with mild-moderate chronic renal insufficiency: pooled analysis of the randomized trials.	2005-07	15926184
Effects of hyperosmolar ionic and low osmolar non-ionic contrast media on acid base, blood gas and electrolyte status in dogs.	2004-06	15315703
Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography.	2003-12	14624421
Effects of hyperosmolar ionic and low osmolar non-ionic contrast media on coagulation times and some blood parameters in dogs: an in vivo study.	2003-08	12887624
[Prospects of the use of non-ionic X-ray contrast media during endoscopic retrograde cholangiopancreatography].	2003-05-02	12722628
Reactions to radiocontrast media.	2002-12-13	12476546
[A state of delirium (confusion) following cerebral angiography with ioxilan: a case report].	2002-06	12136638
Stabilization of the hydrophilic sphere of non-ionic monomers: are all protected in a similar way?	2001-12	11777766
Toward proteomics in uroscopy: urinary protein profiles after radiocontrast medium administration.	2001-05	11316862
Effects of nonionic contrast media on platelet aggregation: assessment by particle counting with laser-light scattering.	2001-01	11324800

Patents

Sample Use Guides

In Vivo Use Guide

300 mgI/mL or 350 mgI/mL injection

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:27:47 GMT 2025` Edited by `admin` on `Mon Mar 31 18:27:47 GMT 2025`
Record UNII	A4YJ7J11TG
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IOXILAN

Official Name

English

OXILAN-300

Preferred Name

English

N-(2,3-DIHYDROXYPROPYL)-5-(N-(2,3-DIHYDROXYPROPYL)ACETAMIDO)-N'-(2-HYDROXYETHYL)-2,4,6-TRIIODOISOPHTHALAMIDE

Systematic Name

English

IOXILAN [MI]

Common Name

English

IOXILAN [JAN]

Common Name

English

OXILAN

Brand Name

English

IOXILAN [USP MONOGRAPH]

Common Name

English

IOXILAN [USAN]

Common Name

English

1,3-BENZENEDICARBOXAMIDE, 5-(ACETYL(2,3-DIHYDROXYPROPYL)AMINO)-N-(2,3-DIHYDROXYPROPYL)-N'-(2-HYDROXYETHYL)-2,4,6-TRIIODO-

Systematic Name

English

IOXILAN [USP IMPURITY]

Common Name

English

ioxilan [INN]

Common Name

English

IOXILAN [VANDF]

Common Name

English

NSC-760056

Code

English

Ioxilan [WHO-DD]

Common Name

English

IOXILAN [MART.]

Common Name

English

LOXILAN [VANDF]

Common Name

English

IOXITOL

Common Name

English

IOXILAN [USP-RS]

Common Name

English

IOXILAN [ORANGE BOOK]

Common Name

English

1,3-BENZENEDICARBOXAMIDE, 5-(ACETYL(2,3-DIHYDROXYPROPYL)AMINO)-N1-(2,3-DIHYDROXYPROPYL)-N3-(2-HYDROXYETHYL)-2,4,6-TRIIODO-

Systematic Name

English

Classification Tree Code System Code

WHO-VATC

QV08AB12